1035 related articles for article (PubMed ID: 27883117)
21. [PDE5: A new therapeutic target for lower urinary tract symptoms/ benign prostatic hyperplasia combined with erectile dysfunction].
Xu Z; Jia RP
Zhonghua Nan Ke Xue; 2018 Apr; 24(4):355-359. PubMed ID: 30168958
[TBL] [Abstract][Full Text] [Related]
22. Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis.
Wang X; Wang X; Li S; Meng Z; Liu T; Zhang X
PLoS One; 2014; 9(9):e107593. PubMed ID: 25216271
[TBL] [Abstract][Full Text] [Related]
23. [Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].
Descazeaud A; Barry Delongchamps N; Cornu JN; Azzouzi AR; Buchon D; Benchikh A; Coloby P; Dumonceau O; Fourmarier M; Haillot O; Lebdai S; Mathieu R; Misrai V; Saussine C; de La Taille A; Robert G;
Prog Urol; 2015 Jun; 25(7):404-12. PubMed ID: 25841758
[TBL] [Abstract][Full Text] [Related]
24. Study of phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or in combination for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
Sun Y; Peng B; Lei GL; Wei Q; Yang L
Minerva Urol Nefrol; 2020 Feb; 72(1):13-21. PubMed ID: 31241273
[TBL] [Abstract][Full Text] [Related]
25. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
Miner M; Rosenberg MT; Perelman MA
Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
[TBL] [Abstract][Full Text] [Related]
26. Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis.
Favilla V; Russo GI; Privitera S; Castelli T; Giardina R; Calogero AE; Condorelli RA; La Vignera S; Cimino S; Morgia G
Aging Male; 2016 Sep; 19(3):175-181. PubMed ID: 27310433
[TBL] [Abstract][Full Text] [Related]
27. Current pharmacological treatment options for male lower urinary tract symptoms.
Strittmatter F; Gratzke C; Stief CG; Hedlund P
Expert Opin Pharmacother; 2013 Jun; 14(8):1043-54. PubMed ID: 23641819
[TBL] [Abstract][Full Text] [Related]
28. Medical treatment of lower urinary tract symptoms/benign prostatic hyperplasia: anything new in 2015.
Schauer I; Madersbacher S
Curr Opin Urol; 2015 Jan; 25(1):6-11. PubMed ID: 25393269
[TBL] [Abstract][Full Text] [Related]
29. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
[TBL] [Abstract][Full Text] [Related]
30. Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?
Cindolo L; Pirozzi L; Sountoulides P; Fanizza C; Romero M; Castellan P; Antonelli A; Simeone C; Tubaro A; de Nunzio C; Schips L
BMC Urol; 2015 Sep; 15():96. PubMed ID: 26391357
[TBL] [Abstract][Full Text] [Related]
31. Treatment of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction.
Calogero AE; Burgio G; Condorelli RA; Cannarella R; La Vignera S
Aging Male; 2018 Dec; 21(4):272-280. PubMed ID: 29378485
[TBL] [Abstract][Full Text] [Related]
32. PDE-5 Inhibitors for BPH-Associated LUTS.
Brousil P; Shabbir M; Zacharakis E; Sahai A
Curr Drug Targets; 2015; 16(11):1180-6. PubMed ID: 26470799
[TBL] [Abstract][Full Text] [Related]
33. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Gacci M; Vittori G; Tosi N; Siena G; Rossetti MA; Lapini A; Vignozzi L; Serni S; Maggi M; Carini M
J Sex Med; 2012 Jun; 9(6):1624-33. PubMed ID: 22510238
[TBL] [Abstract][Full Text] [Related]
34. Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH.
Wang XH; Wang X; Shi MJ; Li S; Liu T; Zhang XH
Asian J Androl; 2015; 17(6):1022-32. PubMed ID: 25994648
[TBL] [Abstract][Full Text] [Related]
35. Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia.
Zabkowski T; Saracyn M
J Physiol Pharmacol; 2018 Aug; 69(4):. PubMed ID: 30552307
[TBL] [Abstract][Full Text] [Related]
36. Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action.
Yamaguchi O
Int J Urol; 2013 Jan; 20(1):28-39. PubMed ID: 23190275
[TBL] [Abstract][Full Text] [Related]
37. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.
Oudot A; Oger S; Behr-Roussel D; Caisey S; Bernabé J; Alexandre L; Giuliano F
BJU Int; 2012 Nov; 110(9):1352-8. PubMed ID: 22448674
[TBL] [Abstract][Full Text] [Related]
38. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment.
Schulman CC
Urology; 2003 Sep; 62(3 Suppl 1):24-33. PubMed ID: 12957197
[TBL] [Abstract][Full Text] [Related]
39. Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia.
De Nunzio C; Salonia A; Gacci M; Ficarra V
World J Urol; 2020 Nov; 38(11):2771-2779. PubMed ID: 32060633
[TBL] [Abstract][Full Text] [Related]
40. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
